+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of treatment with single total-dose intravenous iron versus daily oral iron(III)-hydroxide polymaltose on moderate puerperal iron-deficiency anemia



Effect of treatment with single total-dose intravenous iron versus daily oral iron(III)-hydroxide polymaltose on moderate puerperal iron-deficiency anemia



Therapeutics and Clinical Risk Management 13: 647-653



Iron-deficiency anemia is the most common nutritional cause of anemia in pregnancy and is often responsible for puerperal anemia. Puerperal anemia can impair postpartum maternal and neonatal well-being. To determine the effect of treatment of moderate puerperal iron-deficiency anemia using a single intravenous total-dose iron dextran versus daily single dose oral iron(III)-hydroxide polymaltose. A randomized controlled study in which postpartum women with moderate iron-deficiency anemia were randomized into treatment with either a single total-dose intravenous iron dextran or with daily single doses of oral iron(III)-hydroxide polymaltose tablets for 6 weeks. Effects on hemoglobin concentration using either method were compared at 6 weeks postpartum. Analysis was per protocol using SPSS version 17 for windows. P-values ≤0.05 were considered significant. Two hundred eighty-four women were recruited for the study: 142 women received single total dose intravenous infusion of iron dextran while 142 received daily oral iron(III)-hydroxide polymaltose tablets. Approximately 84.0% (237/282) completed the study and were analyzed including 81% (115/142) of those randomized to injectable iron therapy compared to 85.9% (122/142) of those randomized to oral treatment. The proportions of women who had attained hemoglobin concentration of at least 10 g/dL by the 6 weeks postpartum visit did not differ significantly between cases and controls (95.7% vs 94.3%; P=0.73). Similarly, the mean increases in hemoglobin following either therapeutic route were comparable (1.03±0.56 g/dL for intravenous iron and 0.97±0.46 g/dL for the oral group; P=0.42). Single total-dose intravenous iron for treatment of puerperal iron-deficiency anemia was as effective as daily single doses of ferric iron tablets. For puerperal patients with iron-deficiency anemia in whom compliance with and tolerability of oral iron are not certain, a single total-dose intravenous iron can be safely offered.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059655335

Download citation: RISBibTeXText

PMID: 28761350

DOI: 10.2147/tcrm.s112227


Related references

Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia / a single-centre randomized controlled isotope study. Arzneimittel-Forschung 57(6a): 392-400, 2007

Effect of oral tetracycline on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia / a single-centre randomized controlled isotope study. Arzneimittel-Forschung 57(6a): 376-384, 2007

A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy. Seminars in Hematology 55(4): 223-234, 2018

Effect of an oral iron(III)-hydroxide polymaltose complex on tetracycline pharmacokinetics in patients with iron deficiency anemia. Arzneimittel-Forschung 57(6a): 385-391, 2007

A comparative study of iron salts vs hydroxide polymaltose iron complex efficacy in the treatment of iron deficiency anemia in presenile and senile patients. Gematologiya i Transfuziologiya 49(1): 29-32, January-February, 2004

Comparative study of tolerability and efficacy of iron protein succinylate versus iron hydroxide polymaltose complex in the treatment of iron deficiency in children. International Journal of Clinical Pharmacology and Therapeutics 36(6): 320-325, 1998

Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology 12(3): 255-256, 2007

Intravenous iron polymaltose complex for treatment of iron deficiency anaemia in pregnancy resistant to oral iron therapy. European Journal of Haematology 64(4): 272-274, 2000

A randomized clinical trial of the efficacy of single versus double-daily dose of oral iron for prevention of iron deficiency anemia in women with twin gestations. Journal of Maternal-Fetal and Neonatal Medicine 30(23): 2884-2889, 2017

Total dose iron dextran infusion versus oral iron for treating iron deficiency anemia in pregnant women: a randomized controlled trial. Journal of Maternal-Fetal and Neonatal Medicine 32(3): 398-403, 2019

Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. Journal of Obstetrics and Gynaecology Research 39(2): 504-510, 2013

Iron hydroxide polymaltose: iatrogenic cause of persistent iron deficiency anaemia despite continuous oral iron therapy. Journal of the Association of Physicians of India 50: 279-280, 2002

Efficacy, Tolerability, and Acceptability of Iron Hydroxide Polymaltose Complex versus Ferrous Sulfate: A Randomized Trial in Pediatric Patients with Iron Deficiency Anemia. International Journal of Pediatrics 2011: 524520, 2011

Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. Journal of the American Society of Nephrology 9(4): 664-668, 1998

Efficacy and safety of intravenous iron polymaltose in the treatment of iron deficiency anemia. Blood 92(10 Suppl. 1 Part 1-2): 24B, 1998